Pharmacogenetic Perspectives: Genes, Drugs and Disease
Authors: Elliot S. Vesell
Journal: Hepatology (1984)

HepatologyVolume 4, Issue 5 p. 959-965 Special ArticlesFree Access Pharmacogenetic Perspectives: Genes, Drugs and Disease Elliot S. Vesell, Corresponding Author Elliot S. Vesell Department of Pharmacology, The Pennsylvania State University, College of Medicine, Hershey, Pennsylvania 17033Elliot S. Vesell, M.D., Department of Pharmacology, The Pennsylvania State University, College of Medicine, Hershey, Pennsylvania 17033.===Search for more papers by this author Elliot S. Vesell, Corresponding Author Elliot S. Vesell Department of Pharmacology, The Pennsylvania State University, College of Medicine, Hershey, Pennsylvania 17033Elliot S. Vesell, M.D., Department of Pharmacology, The Pennsylvania State University, College of Medicine, Hershey, Pennsylvania 17033.===Search for more papers by this author First published: September‐October 1984 https://doi.org/10.1002/hep.1840040530Citations: 14AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat References 1 Fausto N, Shank PR. Oncogene expression in liver regeneration and hepatocarcinogenesis. Hepatology 1983; 3: 1016– 1023. 2 Weinberg RA. A molecular basis of cancer. Sci Am 1983; 249: 126– 142. 3 Svejgaard A, Hauge M, Jersild C, et al. The HLA system: an introductory survey. In: L Beckman, M Hauge, Umea Hauge, et al., eds. Monographs in human genetics, Vol 7. Basel (Switzerland): S. KargerAG, 1975: 1– 100. 4 Bodmer WF. Inheritance of susceptibility to cancer in man. Oxford: Oxford University Press, 1983. 5 Kalow W. Pharmacogenetics: heredity and the response to drugs. Philadelphia: W. B. Saunders, 1962. 6 Motulsky A. Pharmacogenetics. Progr Med Genet 1964; 3: 49– 74. 7 Vesell ES. Advances in pharmacogenetics. Prog Med Genet 1973; 9: 291– 367. 8 Vesell ES, Penno MB. Assessment of methods to identify sources of interindividual pharmacokinetic variations. Clin Pharmacokinet 1983; 8: 378– 409. 9 LaDu BN. Pharmacogenetics: defective enzymes in relation to reactions to drugs. Ann Rev Med 1972; 23: 453– 468. 10 Symposia on Human pharmacogenetics and New Directions in Pharmacogenetics. (Weinshilboum RM, Vesell ES, eds). Fed Proc 1984; 43: 2295– 2347. 11 Penno MB, Dvorchik BH, Vesell ES. Genetic variation in rates of antipyrine metabolite formation: a study in uninduced twins. Proc Natl Acad Sci USA 1981; 78: 5193– 5196. 12 Vesell ES, Page JG. Genetic control of drug levels in man: antipyrine. Science 1968; 161: 72– 73. 13 Vesell ES, Page JG. Genetic control of drug levels in man: phenylbutazone. Science 1968; 159: 1479– 1480. 14 Vesell ES, Page JG. Genetic control of dicoumarol levels in man. J Clin Invest 1968; 47: 2657– 2663. 15 Vesell ES, Page JG, Passananti GT. Genetic and environmental factors affecting ethanol metabolism in man. Clin Pharmacol Ther 1971; 12: 192– 201. 16 Cascorbi HF, Vesell ES, Blake DA, et al. Genetic and environmental influence on halothane metabolism in twins. Clin Pharmacol Ther 1971; 12: 50– 55. 17 Alexanderson B, Price Evans DA, Sjoqvist F. Steady-state plasma levels of nortriptyline in twins. Influence of genetic factors and drug therapy. Br Med J 1969; 4: 764– 768. 18 Endrenyi L, Inaba T, Kalow W. Genetic study of amobarbital elimination based on its kinetics in twins. Clin Pharmacol Ther 1976; 20: 701– 714. 19 Andreasen PB, Froland A, Skovsted L, et al. Diphenylhydantoin half-life in man and its inhibition by phenylbutazone: the role of genetic factors. Acta Med Scand 1973; 193: 561– 564. 20 Furst DE, Gupta N, Paulus HE. Salicylate metabolism in twins: evidence suggesting a genetic influence and induction of salicylur-ate formation. J Clin Invest 1977; 60: 32– 42. 21 Scott J, Poffenbarger PL. Pharmacogenetics of tolbutamide metabolism in humans. Diabetes 1979; 28: 41– 51. 22 Whittaker JA, Price Evans DA. Genetic control of phenylbutazone metabolism in man. Br Med J 1970; 4: 323– 328. 23 Asberg M, Price Evans DA, Sjoqvist F. Genetic control of nortriptyline kinetics in man: a study of relative of propositi with high plasma concentrations. J Med Genet 1971; 8: 129– 135. 24 Alvares AP, Schilling G, Levin W, et al. Cytochromes P-450 and b5 in human liver microsomes. Clin Pharmacol Ther 1969; 10: 655– 659. 25 Lu AYH, Levin W. The resolution and reconstitution of the liver microsomal hydroxylation system. Biochim Biophys Acta 1974; 344: 205– 240. 26 Nebert DW, Negishi M, Lang MA, et al. The Ah locus, a multigene family necessary for survival in a chemically adverse environment: comparison with the immune system. Adv Genet 1982; 21: 1– 52. 27 Ryan D, Lu AYH, Kawalek J, et al. Highly purified cytochrome P-448 and P-450 from rat liver microsomes. Biochem Biophys Res Commun 1975; 64: 1134– 1141. 28 Wang P, Mason PS, Guengerich FP. Purification of human liver cytochrome P-450 and comparison to the enzyme isolated from rat liver. Arch Biochem Biophys 1980; 199: 206– 219. 29 Mahgoub A, Idle JR, Dring LD, et al. The polymorphic hydroxylation of debrisoquine in man. Lancet 1977; 2: 584– 586. 30 Eichelbaum M, Spannbrucker N, Steinecke B, et al. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 1979; 18: 183– 187. 31 Idle JR, Sloan TP, Smith RL, et al. Application of the phenotyped panel approach to the detection of polymorphism of drug oxidation in man. Br J Pharmacol 1979; 66: 430– 431P. 32 Bertilsson L, Eichelbaum M, Mellstrom B, et al. Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. Life Sci 1980; 27: 1673– 1677. 33 Mellstrom B, Bertilsson L, Sawe J, et al. E- and Z-10-hydroxylation of nortriptyline: Relationship to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther 1981; 30: 189– 193. 34 Sloan TP, Mahgoub A, Lancaster R, et al. Polymorphism of carbon oxidation of drugs and clinical implications. Br Med J 1978; 2: 655– 657. 35 Shah RR, Oates NS, Idle JR, et al. Genetic impairment of phenformin metabolism. Lancet 1980; 1: 1147. 36 Alvan G, Von Bahr C, Seideman P, et al. High plasma concentrations of β-receptor blocking drugs and deficient debrisoquine hydroxylation. Lancet 1982; 1: 333. 37 Shah RR, Oates NS, Idle JR, et al. Beta-blockers and drug oxidation status. Lancet 1982; 1: 508– 509. 38 Shah RR, Oates NS, Idle JR, et al. Impaired oxidation of debrisoquine in patients with perhexiline neuropathy. Br Med J 1982b; 284: 295– 299. 39 Wang T, Roden M, Wolfenden HT, et al. Influence of genetic polymorphism on the metabolism and disposition of encainide in man. J Pharmacol Exp Ther 1984; 228: 605– 611. 40 Panayi GS, Huston G, Shah RR, et al. Deficient sulphoxidation status and D-penicillamine toxicity. Lancet 1983; 1: 414. 41 Idle JR, Oates NS, Shah RR, et al. Protecting poor metabolisers, a group at high risk of adverse drug reactions. Lancet 1983; 1: 1388. 42 Jack DB, Kendall MJ, Wilkins MR. Drug reactions and the poor metaboliser. Lancet 1983; 2: 110. 43 Kalow W, Kadar D, Inaba T, et al. A case of deficiency of N-hydroxylation of amobarbital. Clin Pharmacol Ther 1977; 21: 530– 535. 44 Kalow W. Pharmacoanthropology: drug metabolism. Fed Proc 1984; 43: 2326– 2331. 45 Woolhouse NM, Andoh B, Mahgoub A, et al. Debrisoquin hydroxylation polymorphism among Ghanaians and Caucasians. Clin Pharmacol Ther 1979; 26: 584– 591. 46 Inaba T, Otton SV, Kalow W. Debrisoquine hydroxylation capacity: problems of assessment in two populations. Clin Pharmacol Ther 1981; 29: 218– 223. 47 Sloan TP, Lancaster R, Shah RR, et al. Genetically determined oxidation capacity and the disposition of debrisoquine. Br J Clin Pharmacol 1983; 15: 443– 450. 48 Davies DS, Kahn GC, Murray S, et al. Evidence for an enzymatic defect in the 4-hydroxylation of debrisoquine by human liver. Br J Clin Pharmacol 1981; 11: 89– 91. 49 Meier PJ, Mueller HK, Dick B, et al. Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation. Gastroenterology 1983; 85: 682– 692. 50 Conney AH, Levin W. Pharmacological and toxicological implications of multiple cytochromes P-450. In: H Yoshida, Y Hagihara, S Ebashi, eds. Advances in pharmacology and therapeutics II (Proceeding of IUPHAR 8th International Congress of Pharmacology), Vol IV. Oxford: Pergamon Press, 1982: 99– 118. 51 Eichelbaum M. Polymorphic drug oxidation in humans. Fed Proc 1984; 43: 2298– 2302. 52 Shahidi NT. Acetophenetidin sensitivity. Am J Dis Chil 1964; 113: 81– 82. 53 Penno MB, Vesell ES. Monogenic control of variations in antipyr-ine metabolite formation: New polymorphism of hepatic drug oxidation. J Clin Invest 1983; 71: 1698– 1709. 54 Bertilsson L, Eichelbaum M, Mellstrom B, et al. Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. Life Sci 1980; 27: 1673– 1677. 55 Danhof M, Idle JR, Tennissen MWC, et al. Influence of the genetically controlled deficiency in debrisoquine hydroxylation on antipyrine metabolite formation. Pharmacology 1981; 22: 349– 358. 56 Danhof M, Krom DP, Breimer DD. Studies on the different metabolic pathways of antipyrine in rats: influence of phenobarbital and 3-methylcholanthrene treatment. Xenobiotica 1979; 9: 695– 702. 57 Inaba T, Lucassen M, Kalow W. Antipyrine metabolism in the rat by three hepatic monooxygenases. Life Sci 1980; 26: 1977– 1983. 58 Vesell ES. Selection of subjects for investigation of host factors affecting drug response: A method to identify new pharmacogenetic conditions. Clin Pharmacol Ther 1984; 35: 1– 11. 59 Smeraldi E, Bellodi L, Saccheti E, et al. The HLA system and the clinical response to treatment with chlorpromazine. Br J Psychiatry 1976; 129: 486– 489. 60 Smeraldi E, Scorza-Smeraldi R. Interference between anti-HLA antibodies and chlorpromazine. Nature 1976; 260: 532– 533. 61 Perris C, Strandman E, Wahlby L. HLA antigens and the response to prophylactic lithium. Neuropsychobiology 1979; 5: 114– 118. 62 Wooley PH, Griffin J, Panayi GS, et al. HLA-DR antigens and toxic reaction to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis. N Engl J Med 1980; 303: 300– 302. 63 Schmidt KL, Mueller-Eckhardt C. Agranulocytosis, levamisole, and HLA-B27. Lancet 1977; 2: 85. 64 Batchelor JR, Welsh KI, Mansilla Tinoco R, et al. Hydralazine-induced systemic lupus erythematosus: influence of HLA-DR and sex on susceptibility. Lancet 1980; 1: 1107– 1109. 65 Perry HM, Tan EM, Carmody S, et al. Relationship of acetyl transferase activity to antinuclear antibodies and toxic symptoms in hypertensive patients treated with hydralazine. J Lab Clin Med 1970; 76: 114– 125. 66 Wolff PH. Ethnic differences in alcohol sensitivity. Science 1972; 175: 449– 450. 67 Chen KK, Poth EJ. Racial differences as illustrated by the mydriatic action of cocaine, euphthalmine, and ephidrine. J Pharmacol Exp Ther 1929; 36: 429. 68 Spector R, Choudhury AK, Chiang CK, et al. Diphenhydramine in Orientals and Caucasians. Clin Pharmacol Ther 1980; 28: 229– 234. 69 Roninson IB, Abelson HT, Housman DE, et al. Amplification of specific DNA sequences correlates with multi-drug resistance in Chinese hamster cells. Nature 1984; 309: 626– 628. Citing Literature Volume4, Issue5September‐October 1984Pages 959-965 ReferencesRelatedInformation